Chen X, Wu Y, Zhong D, Li L, Tan T, Xie X, Yan C, Li X
Academia Sinica, Chengdu Institute of Organic Chemistry.
Hua Xi Yi Ke Da Xue Xue Bao. 1992 Sep;23(4):420-3.
Nine patients with inoperable hepatoma were treated by using hepatic arterial embolization 131I and chemotherapeutic agent gelatin microsphere (131I-CA-GM). The emission CT after operation detected that the microspheres were concentrated on tumor area. The ratio between the radioactivity in tumor and that in liver was 4.1:1. A case died of ictopic embolization; the others survived 3, 4, 5, 19, 24, 7, 8, and 12 months respectively. Three of them were still alive. 131I-CA-GM has triple anticarcinogenic actions, including the arterial occlusion, targeting chemotherapy and internal radiation. The microspheres can selectively accumulate in the tumor artery and can be easily traced by gamma-camera or emission CT. 131I-CA-GM is a hopeful embolic agent for the treatment of liver cancer, but some problems about ectopic arterial embolization should be further studied.
9例无法手术切除的肝癌患者接受了肝动脉栓塞131I与化疗药物明胶微球（131I-CA-GM）联合治疗。术后发射型计算机断层扫描（ECT）检测到微球集中在肿瘤区域。肿瘤与肝脏放射性之比为4.1:1。1例死于异位栓塞；其他患者分别存活3、4、5、19、24、7、8和12个月。其中3例仍存活。131I-CA-GM具有动脉闭塞、靶向化疗和内照射三重抗癌作用。微球可选择性地在肿瘤动脉中积聚，并且可以通过γ相机或发射型计算机断层扫描轻松追踪。131I-CA-GM是一种有希望用于治疗肝癌的栓塞剂，但关于异位动脉栓塞的一些问题仍需进一步研究。
